

OFFICE MEMORANDUM

TO: Dr. C. S. Rowland
Mr. J. F. Fitzsimmons
Mr. R. J. Grimm
Mr. E. F. Milardo
Mr. G. A. Sprott
Mr. R. C. Wolfe
Mr. Bennett Woods
Dr. R. C. Reardon
Dr. C. L. Goldman
Dr. Yale Gressel
Mr. E. G. Shay

FROM: L. B. Copeland


DATE: 9-2-75

SUBJECT: CTFA Standards Committee Meeting

Attached are the minutes of the August CTFA Standards Committee Meeting.

Next meeting is planned for September 25, 1975 at the Chemist's Club in New York City.

LBC:mg
Att:



cc: R.A. Baliatico (6)
J.J. Travers
Richard Kaplan
F.R. McLaughlin
E.F. Schneider
R.J. Thabit
J.C. Anderson
J.A. Barrans
C.P. Randa
P.T. Town
Donald Orgen
R.J. Dexheimer
R&D Central Files



The Cosmetic, Toiletry and Fragrance Association, Inc.

1133 15th STREET, N.W., WASHINGTON, D.C. 20005 • 202/331-1770 • TELEX 89-2673

James H. Merritt
President

Norman F. Estrin, Ph.D.
Vice President—Science

CTFA STANDARDS COMMITTEE

M I N U T E S

A meeting of the CTFA Standards Committee was held on August 21, 1975 at the Chemists' Club in New York City. Those in attendance were:

Dr. Reisberg, Carter Products (Chairman)
Mr. Dave Conrad, Amway Corp.
Mr. Lloyd Copeland, Avon Products
Mr. Corky Desmond, Union Carbide (for Dr. McKenzie)
Mr. Richard Dexheimer, Avon
Dr. John Gibbs, Noxell Corp.
Mr. Robert Kelley, Colgate-Palmolive
Mr. Albert Kopf, Clairol, Inc.
Dr. Fred Lohman, Procter & Gamble
Mr. Monroe Messinger, Chesebrough-Pond's
Mr. George Sandland, Bristol-Myers
Mr. Al Wich, Elizabeth Arden
Dr. Norman Estrin, CTFA

Guests present were:

Mr. Ray Krammes, Whittaker, Clark & Daniels
Mr. G. Lee, Johnson & Johnson
Dr. D. Petterson, Johnson & Johnson
Dr. R. Rolle, Johnson & Johnson
Mr. J. Woodward, Johnson & Johnson

Absent from this meeting were:

Mr. Salvatore DiBianca, American Can
Mr. Charles Fairchild, Revlon Research
Dr. Dale McKenzie, Union Carbide
Mr. Richard Schroeder, Personal Products

1. Talc Subcommittee

Mr. Sandland described meetings of the Talc Subcommittee and the recommended standard.

Dr. Petterson described the origin of the "90% figure" and its relationship to safety investigations completed.

Dr. Estrin proposed consideration of preparation of two standards, one for aerosol talc (which would include the 90% figure) and one for cosmetic talc, which would be more broadly defined. Mr. Ray Krammes (Whittaker, Clark & Daniels) responded that if such a standard were adopted his company could not supply the "aerosol talc."

Amphibole Specification

After extensive discussion of advantages and disadvantages of listing a 0.5% maximum limit as opposed to "nondetected" terminology, the Standards Committee voted for the use of the "nondetected" terminology against a recommendation offered by Johnson & Johnson scientists.

Free Crystalline Silica Specification

The Standards Committee voted for a free crystalline silica specification, as specified by the buyer, with a method to be supplied.

Identification

The Committee voted to include the term "positive close match to CTFA Spectrum - IR with no indication of foreign materials."

Definition

The definition was revised as follows: "Cosmetic talc is a white, essentially odorless, fine powder, ground from naturally occurring rock ore, consisting mainly of hydrated magnesium silicate having the ideal formula $Mg_6(Si_8O_{20}) \cdot (OH)_4$ with lesser amounts of naturally associated minerals such as dolomite, magnesite, chloride, calcite and aluminum silicate and containing no detectable fibrous asbestos minerals." (The preceding definition was changed on August 22 as a result of a call from Ray Krammes (Whittaker, Clark & Daniels), who informed me that the term he proposed for inclusion, i.e., alumina was incorrect and should in fact be aluminum silicate.)

The Standards Committee voted for the above definition despite the recommendation from Johnson & Johnson scientists that a narrower definition be developed.

Methodology

Dr. Rolle distributed and discussed methodology he drafted for fibrous amphiboles. He was complimented for his impressive contribution to the Standards Committee. The Committee agreed to approve the methodology except for small editorial changes to be worked out by Dr. Rolle and Mr. Copeland. Members of the Committee were urged to call Dr. Rolle with suggestions and comments on the methodology within the week.

Mr. Sandland was complimented on his leadership as chairman of the Talc Subcommittee.

2. Specifications

Proposed specifications for morpholine and formaldehyde was distributed and discussed by Mr. Wich, who asked Committee members to study the drafts and make recommendations.

Specifications on hydrolyzed animal protein and methyl salicylate, forwarded by Mr. DiBianca, were distributed to the Committee for discussion.

3. Cosmetic Analysis Study Group

Dr. Estrin reported on the renewal of efforts by FDA to republish a revision of Sylvan Newburger's A Manual of Cosmetic Analysis. (Copies of FDA's letter and minutes will be sent to Committee members. Dr. Reisberg was asked to give consideration to reactivating a committee.

4. Ingredients Under Study

Dr. Reisberg asked Committee members to send him a list of materials currently being worked on by Standards Committee members.

5. Cosmetic Ingredient Descriptions

Dr. Lohman described the activities of his subcommittee and their plans to utilize FDA's list of ingredients as a source of information on ingredients currently being used by the cosmetic industry.

6. REAS Program

Dr. Estrin described briefly the expected needs for a chemical description subcommittee.